UCB's Head of Corporate Strategy On Deals, Divestments And Sector-Wide Challenges
Executive Summary
UCB's recently appointed head of corporate strategy and business development Alexander Moscho, who joined the company in October 2017, talks to Scrip about UCB's future growth, internal R&D pipeline and potential for significant deal-making in 2018.
You may also be interested in...
UCB Looks To Its Next Wave Of Innovative Products
Early clinical-stage products for neurological and autoimmune diseases are progressing through the European biopharma's pipeline.
Deal Watch: Fresenius Drops Bid For Akorn, Citing Data-Integrity Concerns
Janssen and Bristol team to develop next-generation oral anticoagulant, while UCB buys Proximagen's nasal spray candidate and Duke spinout focused on genomics.
Rise of the patient affairs officer; Sanofi makes appointment
Following the growing trend of pharmaceutical companies embracing patient-centric business models, Sanofi has appointed Dr Anne C Beal chief of patient affairs. The French pharma is the first of the top ten biopharmaceutical companies to create space for such a position, according to Pascale Witz executive vice-president of global and strategic development.